Reduction in myocardial infarct size at 48 hours after brief intravenous infusion of ATL-146e, a highly selective adenosine A2A receptor agonist

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 2, 2009, Pages

  Patel, Rajan A G ^a   Glover, David K ^a,d   Broisat, Alexis ^a   Kabul, Hasan K ^a   Ruiz, Mirta ^a   Goodman, N Craig ^a   Kramer, Christopher M ^a,b   Meerdink, Denis J ^c   Linden, Joel ^a   Beller, George A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Myocardial infarction; Reperfusion injury

Indexed keywords

4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; MALE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BLOOD PRESSURE; COMBINED MODALITY THERAPY; CORONARY CIRCULATION; CYCLOHEXANECARBOXYLIC ACIDS; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; MALE; METOPROLOL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDITIS; NEUTROPHILS; PURINES; RECEPTOR, ADENOSINE A2A; TIME FACTORS; TROPONIN I; VENTRICULAR FIBRILLATION;

EID: 68049100399     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00705.2008     Document Type: Article

References (29)

1. Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ. A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol Heart Circ Physiol 285: H607-H613, 2003. (Pubitemid 36885891)
2. 2A receptor in the modulation of myocardial reperfusion damage. J Cardiovasc Pharmacol 33: 883-893, 1999.
3. Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, Tincey S, Michael LH, Entman ML, Frangogiannis NG. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 164: 665-677, 2004. (Pubitemid 38364680)
4. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, Ganz W. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 101: 593-600, 1981. (Pubitemid 11120523)
5. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 13: 1877-1893, 2006.
6. 2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol 288: H1851-H1858, 2005.
7. 2A adenosine receptor agonists ATL193 and ATL146e administered by either intravenous infusion or bolus injection. Circulation 104: 1181-1187, 2001.
8. 3 adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol Heart Circ Physiol 277: H1895-H1905, 1999.
9. Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 280: 301-309, 1997. (Pubitemid 27171416)
10. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, Zhao ZQ, Guyton RA, Headrick JP, Vinten-Johansen J. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67: 124-133, 2005. (Pubitemid 40798299)
11. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 203: 2639-2648, 2006. (Pubitemid 44833340)
12. 2a agonist CGS-21680 in infarcted and stunned porcine myocardium. Am J Physiol Heart Circ Physiol 280: H1660-H1666, 2001.
13. 2b receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium. Am J Physiol Heart Circ Physiol 292: H426-H431, 2007.
14. Li L, Huang L, Sung SS, Lobo PI, Brown MG, Gregg RK, Engelhard VH, Okusa MD. NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury. J Immunol 178: 5899-5911, 2007. (Pubitemid 46674387)
15. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41: 775-787, 2001. (Pubitemid 32385906)
16. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34: 1711-1720, 1999.
17. Micari A, Belcik TA, Balcells EA, Powers E, Wei K, Kaul S, Lindner JR. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol 96: 1410-1415, 2005. (Pubitemid 41566624)
18. Norton ED, Jackson EK, Turner MB, Virmani R, Forman MB. The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury. Am Heart J 123: 332-338, 1992.
19. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 105: 656-662, 2002.
20. 2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol 295: H1825-H1833, 2008.
21. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45: 1775-1780, 2005. (Pubitemid 40779856)
22. Schlack W, Schafer M, Uebing A, Schafer S, Borchard U, Thamer V. Adenosine A2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J Cardiovasc Pharmacol 22: 89-96, 1993. (Pubitemid 23178700)
23. 2A receptor agonists. Br J Pharmacol 132: 1017-1026, 2001.
24. Taqueti VR, Mitchell RN, Lichtman AH. Protecting the pump: controlling myocardial inflammatory responses. Annu Rev Physiol 68: 67-95, 2006.
25. 2A-adenosine receptors after myocardial infarction suppresses inflammatory activation and attenuates contractile dysfunction in the remote left ventricle. Am J Physiol Heart Circ Physiol 290: H1410-H1418, 2006.
26. 3 adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Mol Pharmacol 74: 685-696, 2008.
27. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 61: 481-497, 2004. (Pubitemid 38210154)
28. Yang Z, Day YJ, Toufektsian MC, Ramos SI, Marshall M, Wang XQ, French BA, Linden J. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111: 2190-2197, 2005. (Pubitemid 40632434)
29. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007.